Ruxolitinib yog ib tug me me molecule Janus kinase inhibitor uas yog siv nyob rau hauv kev kho mob ntawm nruab nrab los yog siab myelofibrosis thiab resistant cov ntaub ntawv ntawm polycythemia vera thiab graft-vs-host kab mob. Ruxolitinib cuam tshuam nrog kev ncua sijhawm thiab feem ntau me ntsis nce hauv cov ntshav aminotransferase thaum kho thiab rau qee qhov tsis tshua muaj kev txwv ntawm tus kheej, kev kho mob pom tseeb idiosyncratic mob siab rau lub siab nrog rau cov xwm txheej ntawm reactivation ntawm kab mob siab B hauv cov tib neeg uas raug mob.

Ruxolitinib yog ib qho kev hais lus bioavailable Janus-associated kinase (JAK) inhibitor uas muaj peev xwm antineoplastic thiab immunomodulating kev ua ub no. Ruxolitinib tshwj xeeb khi rau thiab inhibits proteintyrosinekinases JAK 1 thiab 2, uas tuaj yeem ua rau txo qis kev mob thiab inhibition ntawm cellular proliferation. JAK-STAT (lub teeb liab transducer thiab activator ntawm transcription) txoj hauv kev plays lub luag haujlwm tseem ceeb hauv kev taw qhia ntawm ntau yam cytokines thiab kev loj hlob thiab koom nrog hauv cellular proliferation, kev loj hlob, hematopoiesis, thiab kev tiv thaiv kab mob; JAK kinases tej zaum yuav raug kho nyob rau hauv cov kab mob inflammatory, myeloproliferative disorders, thiab ntau yam malignancies.

Ruxolitinib yog ibpyrazolehloov ntawm txoj haujlwm 1 los ntawm 2-cyano-1-cyclopentylethyl pawg thiab ntawm txoj haujlwm 3 los ntawm pyrrolo [2,3-d] pyrimidin-4-yl pawg. Siv los ua cov ntsev phosphate rau kev kho mob ntawm cov neeg mob uas muaj kev pheej hmoo nruab nrab lossis muaj kev pheej hmoo siab myelofibrosis, suav nrog thawj myelofibrosis, post-polycythemia vera myelofibrosis thiab post-tseem ceeb thrombocythemia myelofibrosis. Nws muaj lub luag haujlwm ua tus neeg sawv cev antineoplastic thiab EC 2.7.10.2 (tsis yog cov protein tshwj xeeb-tyrosinekinase) inhibitor. Nws yog nitrile, apyrrolopyrimidinethiab ib tug tswv cuab ntawm pyrazoles.